Catalog No.
Product Name
Application
Product Information
Citations
-
Adenosine Analog
2-Amino-N-(3-methyl-2-buten-1-yl)adenosine is an adenosine analog that primarily targets adenosine receptors. This compound exhibits significant smooth muscle vasodilatory activity and has been implicated in the inhibition of cancer progression. It serves as a valuable tool for research in vascular biology and cancer therapeutics, facilitating the exploration of adenosine receptor signaling pathways and their implications in various disease states. -
Adenosine Analog
5’-O-(4,4’-Dimethoxytrityl)-3’-O-t-butyldimethylsilyl adenosine is an adenosine analog that serves as a key modulator of adenosine receptors. This compound exhibits vasodilatory effects on smooth muscle and has potential applications in cancer research due to its ability to inhibit tumor progression. It is particularly useful for studies investigating the roles of adenosine in vascular biology and oncology. -
Adenosine Analog
2-Amino-N6,N6-dimethyl-2’-O-methyladenosine is an adenosine analog that primarily targets adenosine receptors. This compound exhibits smooth muscle vasodilatory effects and has potential applications in inhibiting cancer progression. It is valuable for research in cardiovascular studies and oncology, providing insights into the therapeutic potential of adenosine-related pathways. -
Adenosine Analog
3’-beta-C-Methyl-N6-methyladenosine is an adenosine analog that primarily targets adenosine receptors. This compound exhibits significant smooth muscle vasodilatory effects and has demonstrated potential in inhibiting cancer progression. Its unique structure allows for various research applications, particularly in studies focusing on cardiovascular function and tumor biology. -
Adenosine Analog
8-Allyloxyadenosine is an adenosine analog primarily targeting adenosine receptors. This compound exhibits significant biological activity as a smooth muscle vasodilator and has demonstrated potential in inhibiting cancer progression. It serves as a valuable tool in research applications focused on cardiovascular health and cancer therapy. -
Adenosine Analog
2-(4-Cyanobenzyl)thioadenosine is an adenosine analog that primarily targets adenosine receptors. This compound exhibits potent vasodilatory effects on smooth muscle, making it of interest in cardiovascular research. Additionally, it has demonstrated potential in inhibiting cancer progression, making it a valuable tool for cancer biology studies. -
Adenosine Analog
4’-C-Methyl-N6-methyladenosine is an adenosine analogue that primarily targets adenosine receptors. This compound exhibits significant biological activity as a vasodilator, promoting smooth muscle relaxation, and has shown potential in inhibiting cancer cell progression. It serves as a valuable tool in research applications focused on vascular biology and cancer therapeutics. -
Adenosine Analog
N6-Isopentenyl-2’-C-methyladenosine is an adenosine analog that primarily acts as a vasodilator by influencing adenosine receptors. This compound has demonstrated potential in inhibiting cancer progression, making it valuable for research in oncology and cardiovascular studies. Its unique structure allows for diverse applications in studying nucleotide metabolism and therapeutic interventions targeting adenosine signaling pathways. -
Adenosine Analog
2-(4-Methylbenzyl)thioadenosine is an adenosine analog that primarily targets adenosine receptors. It is recognized for its vasodilatory effects on smooth muscle and demonstrates potential in inhibiting cancer progression. This compound serves as a valuable tool in researching adenosine receptor signaling, cardiovascular function, and cancer biology. -
Adenosine Analog
N-Propargyladenosine is an adenosine analogue that primarily acts as a vasodilator by targeting adenosine receptors. This compound exhibits significant biological activity, demonstrating potential in inhibiting cancer progression. Additionally, N-Propargyladenosine functions as a click chemistry reagent, containing an alkyne group that allows it to undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules, making it valuable for various chemical biology applications. -
Adenosine Analog
3′-O-Methyladenosine is an adenosine analogue that primarily targets adenosine receptors. This compound exhibits significant biological activity as a smooth muscle vasodilator and has also demonstrated potential in inhibiting cancer progression. Its applications extend to various research fields, including cardiovascular studies and oncology, making it a valuable tool for investigating adenosine-related pathways and therapeutic targets. -
Adenosine Analog
2’,3’,5’-Tri-O-acetyl adenosine is an adenosine analog that primarily targets adenosine receptors, serving as a potent smooth muscle vasodilator. This compound has been shown to exert inhibitory effects on cancer progression, making it a valuable tool in oncology research. It is useful for studying adenosine signaling pathways and their implications in various biological processes. -
Adenosine Analog
2,8-Dimethyladenosine is an adenosine analog that primarily targets adenosine receptors. This compound exhibits significant vasodilatory effects on smooth muscle and has demonstrated potential in inhibiting cancer progression. It serves as a valuable tool for research in cardiovascular studies and cancer biology. -
Adenosine Analog
2-Chloro-2′-β-C-methyladenosine is an adenosine analog that primarily targets adenosine receptors. This compound exhibits vasodilatory effects on smooth muscle and demonstrates the potential to inhibit cancer progression. It serves as a valuable tool for research applications focused on vascular biology and cancer therapeutics. -
platelet aggregation inhibitor
Trifenagrel is an orally active platelet aggregation inhibitor that targets the pathways induced by arachidonic acid and collagen. It demonstrates significant biological activity, with ED50 values of 1.4 mg/kg and 9.4 mg/kg for the inhibition of AA- and collagen-induced platelet aggregation in guinea pigs, respectively. This compound serves as a valuable tool in cardiovascular research and the study of thrombotic disorders. -
Platelet-activating Factor Receptor (PAFR) Inhibitor
TSI-01 is a selective inhibitor of the Platelet-activating Factor Receptor (PAFR), targeting lysophosphatidylcholine acyltransferase (LPCAT)2. This compound exhibits a potent inhibitory effect with an IC50 of 0.47 μM for human LPCAT2, significantly more effective than its activity on LPCAT1 (IC50 = 3.02 μM). TSI-01 effectively suppresses PAF biosynthesis in mouse peritoneal macrophages when stimulated with a calcium ionophore at a concentration of 60 μM. This makes TSI-01 a valuable tool for investigating inflammatory processes and related conditions in research applications. -
PAFR Antagonist
MK 287 is a potent and selective antagonist of the platelet-activating factor receptor (PAFR). It effectively inhibits [3H]C18-PAF binding to human platelets, polymorphonuclear leukocytes (PMNs), and lung membranes, with K1 values of 6.1, 3.2, and 5.49 nM, respectively. MK 287 also demonstrates the ability to inhibit PAF-induced platelet aggregation and elastase release from PMNs, with ED50 values of 56, 1.5, and 4.4 nM. This compound is valuable for research focused on cardiovascular diseases, including thrombosis. -
PAF Antagonist
CV-6209 is a potent antagonist of platelet activating factor (PAF) that effectively inhibits PAF-induced aggregation in both rabbit and human platelets, demonstrating IC50 values of 75 nM and 170 nM, respectively. Additionally, CV-6209 has been shown to inhibit PAF-induced hypotension in rat models. This compound is valuable for research focused on platelet function, cardiovascular responses, and PAF-related pathways. -
PAF Agonist
Carbamyl-PAF is an analog and agonist of platelet-activating factor (PAF). It exhibits potent biological activity by stimulating PAF receptors, which play a crucial role in mediating inflammatory responses. Due to its stability and resistance to metabolism in Raji lymphoblasts at 37°C, Carbamyl-PAF is an effective reagent for studying PAF-related signaling pathways and inflammation mechanisms. -
PAF Receptor Antagonist
MoTP is a selective antagonist of the platelet-activating factor (PAF) receptor, known for its ability to induce melanocyte ablation. This compound exhibits significant biological activity that can be leveraged in cancer research, offering insights into melanocyte regulation and tumor microenvironment interactions. MoTP is a valuable reagent for studies aimed at understanding the role of PAF signaling in tumor biology and potential therapeutic strategies. -
Platelet-activating Factor Antagonist
Kadsurenone is a lignan that acts as a specific antagonist of platelet-activating factor (PAF). By inhibiting PAF, Kadsurenone demonstrates potential anti-inflammatory and anti-platelet effects. This compound is commonly explored in research related to cardiovascular disorders and other conditions associated with platelet activation. Kadsurenone can be obtained from the stem of Piper kadsura, providing a natural source for studying its biological activities. -
Platelet Aggregation Inhibitor
2-Acetylbenzoic acid is a derivative of benzoic acid that functions as a weak inhibitor of platelet aggregation. It specifically inhibits adenosine 5'-diphosphate (ADP)-induced platelet aggregation, making it valuable for research in cardiovascular biology and thrombotic disorders. This compound can be utilized to study the role of platelet activation in various disease models and therapeutic interventions. -
PAF Antagonist
TCV-309 chloride is a highly effective antagonist of platelet-activating factor (PAF). It demonstrates specificity in inhibiting PAF-induced aggregation in both rabbit and human platelets, with IC50 values of 33 nM, 58 nM, and 27 nM for the corresponding assays. Additionally, TCV-309 chloride has exhibited potential therapeutic benefits in conditions such as anaphylactic shock, making it a valuable tool for research into PAF-related pathways and inflammatory responses. -
PAF Agonist
Butanoyl PAF is a potent platelet-activating factor (PAF) agonist that retains over 10% of PAF's biological activity. This compound is found in significantly higher concentrations in oxidized low-density lipoprotein compared to enzymatically generated PAF, exceeding it by more than 100-fold. Butanoyl PAF is valuable in research applications aimed at understanding PAF-mediated signaling pathways and their roles in various physiological and pathological processes. -
PAF Receptor Antagonist
α-Bulnesene is a potent PAF receptor antagonist, exhibiting an IC50 of 17.62 μM. Isolated from Pogostemon cablin, it demonstrates significant inhibitory activity against platelet-activating factor and arachidonic acid-induced platelet aggregation in rabbits. This compound is valuable for research exploring the modulation of platelet function and related inflammatory processes. -
PAF Antagonist
Modipafant is a potent and selective platelet-activating factor (PAF) antagonist, known as UK-80067, and represents the (+)-enantiomer of UK-74505. This compound displays approximately double the intrinsic potency of its predecessor, making it a valuable tool in exploring PAF-related biological pathways. Modipafant is primarily utilized in research applications focused on inflammation, cardiovascular disease, and related therapeutic areas. -
PAF Antagonist
CL-184005 is a potent platelet-activating factor (PAF) antagonist that effectively inhibits PAF-induced platelet aggregation, with IC50 values of 600 nM and 510 nM in human and rabbit platelet-rich plasma, respectively. This compound has demonstrated protective effects against endotoxin-induced gastrointestinal damage and hypotension in rat models. Additionally, CL-184005 shows promise in mitigating the effects of Gram-negative bacterial sepsis, making it a valuable tool for research in inflammatory and infectious disease models. -
PAF Antagonist
Clotizolam is a thienobenzodiazepine derivative that acts as an antagonist of platelet-activating factor (PAF). It exhibits sedative, anxiolytic, anticonvulsant, and muscle relaxant properties, making it useful in various research applications related to anxiety and seizure disorders. This compound can be employed in studies aimed at understanding the mechanisms of PAF signaling and its implications in neurological and psychological conditions. -
PAFR Antagonist
Kadsurin A is a novel lignan derived from Piper futokadsura, functioning as a platelet activating factor (PAF) receptor antagonist. It exhibits the ability to inhibit the binding of PAF to its receptor, thereby influencing various biological pathways related to inflammatory responses and cellular signaling. This compound serves as a valuable tool in research applications focused on understanding PAF-related mechanisms and exploring potential therapeutic interventions in related diseases. -
Platelet-activating Factor Receptor (PAFR) Antagonist
BN52115 is a potent antagonist of the platelet-activating factor receptor (PAFR). This compound effectively reduces bronchopulmonary changes in vivo, making it valuable for studies investigating respiratory disorders. Its mechanism of action provides insights into the therapeutic potential for conditions linked to platelet-activating factor signaling. -
PAF Antagonist
SDZ-62-434 free base is a potent platelet-activating factor (PAF) antagonist. It exhibits notable antiproliferative activity against various human solid tumors and hematological malignancies. This compound is relevant for research applications focusing on cancer treatment and the modulation of inflammatory responses mediated by PAF. -
PAFR Partial Agonist
Hexanolamino PAF C-16 is a partial agonist of the Platelet-activating Factor Receptor (PAFR). This compound induces platelet aggregation and promotes macrophage production, while not increasing intracellular calcium levels ([Ca2+]i) in platelets, indicating distinct signaling pathways mediated by PAF receptors. It serves as a valuable tool for research into platelet function and macrophage biology, contributing to the understanding of PAF-related cellular responses. -
PAF Antagonist
Epiyangambin is a competitive antagonist of the platelet activating factor (PAF) receptor, effectively inhibiting PAF-induced platelet aggregation in a dose-dependent manner. Additionally, it demonstrates antiproliferative activity against human colon cancer cells, specifically SW480 cell lines. This dual functionality makes Epiyangambin a valuable tool for research in both vascular biology and cancer studies. -
PAF Receptor Antagonist
BN-50726 is a potent antagonist of the platelet-activating factor (PAF) receptor. It effectively inhibits PAF-induced biological responses, such as [3H]-serotonin release and hypotension, with an IC50 of 5.40 nM. This compound is valuable for research into PAF-mediated pathological processes, including inflammation, anaphylaxis, and hypotensive conditions. -
PAFR Inhibitor
Cryptomeridiol is an inhibitor of the platelet-activating factor (PAF) receptor. It demonstrates significant melanogenesis inhibitory activity in α-MSH-stimulated B16 melanoma cells, making it a valuable tool for research into pigmentation processes and potential therapeutic applications in melanoma. Its mechanisms may contribute to a better understanding of PAF signaling in various biological contexts. -
PAFR Antagonist
rel-(2R,4R)-2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane is a selective antagonist of the platelet-activating factor receptor (PAFR) with an inhibition constant (Ki) of 0.3 µM. This compound exhibits significant biological activity by blocking PAF-mediated signaling pathways. It is useful in research applications exploring inflammatory processes, cardiovascular function, and neurobiology, where PAFR modulation may provide therapeutic insights or novel intervention strategies. -
Platelet Aggregation Inhibitor
Preschisanartanin O is a potent platelet aggregation inhibitor derived from Schisandra lancifolia. It effectively inhibits platelet aggregation induced by platelet-activating factor (PAF), highlighting its potential role in cardiovascular research. This compound is valuable for studies investigating thrombus formation and related pathological conditions, providing insight into therapeutic strategies for managing platelet-related disorders. -
PAF Antagonist
UR-12633 is a potent platelet-activating factor (PAF) antagonist. It effectively reverses hypotension, inhibits coagulation abnormalities, and decreases vascular permeability and metabolic disorders in rodent models of endotoxic shock. This compound is valuable for studying the mechanisms and treatment strategies for endotoxic shock. -
Platelet Aggregation-related Pathway Inhibitor
MKC-963 is a potent, orally active inhibitor targeting platelet aggregation-related pathways. This compound exhibits significant antithrombotic activity by disrupting platelet aggregation mechanisms. Additionally, MKC-963 induces autoinduction of CYP3A4, leading to enhanced metabolism in vivo. It is a valuable tool for research into platelet aggregation-related diseases, such as thrombosis. -
PAF Antagonist
LAU-0901 is a potent PAF receptor antagonist, demonstrating significant neuroprotective properties. This compound effectively inhibits apoptosis, making it a valuable tool for research into neurodegenerative disorders and cell survival mechanisms. Its use in studies related to inflammation and cell signaling pathways highlights its potential for advancing understanding in these areas. -
Platelet Aggregation Inhibitor
(R,R)-MK 287 is a potent platelet aggregation inhibitor targeting platelet-activating factor (PAF) pathways. It demonstrates strong inhibition of PAF binding to human platelets, polymorphonuclear leukocytes, and lung membranes, with Ki values of 6.1, 3.2, and 5.49 nM, respectively. (R,R)-MK 287 effectively prevents PAF-induced platelet aggregation and elastase release from PMNs, with ED50 values of 56 nM and 4.4 nM, respectively. Additionally, it reduces PAF-induced lethality in murine models and bronchospasm in guinea pigs, showcasing its potential applications in inflammatory and cardiovascular research. -
PAF Antagonist
Israpafant is a highly selective and long-acting antagonist of the platelet activating factor (PAF) receptor, demonstrating potent inhibitory effects with IC50 values of 0.84 nM and 3.84 nM against PAF-induced aggregation in human and rabbit platelets, respectively. This compound has been shown to enhance both extracellular calcium influx and intracellular calcium release in prostate cancer cells. Additionally, Israpafant effectively attenuates allergic cutaneous responses, including eosinophilia, cytokine production, edema, and erythema, in murine models. These properties position Israpafant as a valuable tool for investigating PAF-related pathways and allergic reactions. -
Anti-PAF Agent
1,6-Dihydro-4,7-epoxy-1-methoxy-3,4-methylenedioxy-6-oxo-3,8-lignan is a lignan derivative that acts as an anti-platelet-activating factor (PAF) agent. This compound exhibits significant inhibitory effects on PAF, a bioactive lipid involved in inflammatory processes and asthmatic responses. It is valuable in research focused on elucidating the role of PAF in inflammation and developing potential therapeutic strategies for related conditions. -
Arachidonic Acid Metabolism/Platelet Aggregation Inhibitor
Rhazimine is an indole alkaloid that serves as a dual inhibitor of arachidonic acid metabolism and platelet aggregation induced by platelet activating factor. This compound demonstrates significant biological activity by modulating inflammatory pathways and inhibiting platelet aggregation, making it valuable for research in cardiovascular diseases and related pharmacological studies. Rhazimine's mechanism may provide insights into the development of therapeutic strategies targeting vascular inflammation and thrombotic conditions. -
Platelet-Activating Factor Antagonist
Rocepafant is a specific antagonist of platelet-activating factor (PAF), known for its role in modulating inflammatory responses. Its inhibition of PAF activity makes Rocepafant a valuable reagent in studies related to rheumatoid arthritis and neurological conditions. This compound enables researchers to explore mechanisms of inflammation and potential therapeutic strategies in these areas. -
PAF Antagonist
Homoeriodictyol 7-O-β-D-glucoside is a natural antagonist of platelet-activating factor (PAF). It effectively inhibits PAF-induced platelet aggregation in both human and rabbit models, demonstrating an IC50 value of 0.8 μM. This compound is valuable for research exploring the role of PAF in cardiovascular diseases and inflammation. -
platelet-activating factor antagonist
Lexipafant is a potent platelet-activating factor (PAF) antagonist that effectively modulates inflammatory responses. It is primarily utilized in research focused on acute pancreatitis, where it helps elucidate the role of PAF in the inflammatory cascade. This compound serves as a valuable tool in studying the pathophysiology of inflammatory diseases and potential therapeutic interventions. -
PAFR Antagonist
L-659,989 is a highly potent and selective antagonist of the platelet-activating factor receptor (PAFR). Its competitive inhibition of PAFR makes it a valuable tool for studying PAF-mediated biological processes. This compound is applicable in research areas including inflammation, cardiovascular diseases, and cell signaling pathways, providing insights into the role of PAF in various physiological and pathological conditions. -
Platelet-activating Factor Antagonist
E-6123 is a selective platelet-activating factor (PAF) receptor antagonist. It inhibits PAF-mediated signaling pathways, which are implicated in various inflammatory responses and cardiovascular conditions. This compound is valuable for research into inflammation, thrombosis, and related pathologies, making it an essential tool for studying the role of PAF in disease mechanisms. -
Platelet-activating Factor Receptor (PAFR) Antagonist
Bepafant is a specific antagonist of the platelet-activating factor receptor (PAFR) that demonstrates protective effects against anaphylactic lethality in both active and passive anaphylaxis models in mice and guinea pigs. This compound has been shown to reduce bronchoconstriction and mitigate blood pressure alterations associated with anaphylaxis. Bepafant is valuable for research focused on anaphylactic responses and the modulation of PAF-related pathways.
